Floatz logo

Venetoclax

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Children's Hospital Medical Center, CincinnatiSmall moleculePhase 2Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
City of Hope Medical Center
Phase 2BB
Lipitor
Fred Hutchinson Cancer Center
Phase 2B
Midostaurin
M.D. Anderson Cancer Center
Phase 2CCC
Cladribine
M.D. Anderson Cancer Center
Phase 2CCC
Gilteritinib
M.D. Anderson Cancer Center
Phase 2CCC

View all 12 →

Same molecule, other indications

Venetoclax is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
myeloid neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
chronic myelomonocytic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →